AAAAAA

   
Results: 1-8 |
Results: 8
Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel
Authors: Hidalgo, M Aylesworth, C Hammond, LA Britten, CD Weiss, G Stephenson, J Schwartz, G Patnaik, A Smith, L Molpus, K Felton, S Gupta, E Ferrante, KJ Tortora, A Sonnichsen, DS Skillings, J Rowinsky, EK
Citation: M. Hidalgo et al., Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel, J CL ONCOL, 19(9), 2001, pp. 2493-2503
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
Authors: Hidalgo, M Siu, LL Nemunaitis, J Rizzo, J Hammond, LA Takimoto, C Eckhardt, SG Tolcher, A Britten, CD Denis, L Ferrante, K Von Hoff, DD Silberman, S Rowinsky, EK
Citation: M. Hidalgo et al., Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies, J CL ONCOL, 19(13), 2001, pp. 3267-3279
Oral paclitaxel and concurrent cyclosporin A: Targeting clinically relevant systemic exposure to paclitaxel
Authors: Britten, CD Baker, SD Denis, LJ Johnson, T Drengler, R Siu, LL Duchin, K Kuhn, J Rowinsky, EK
Citation: Cd. Britten et al., Oral paclitaxel and concurrent cyclosporin A: Targeting clinically relevant systemic exposure to paclitaxel, CLIN CANC R, 6(9), 2000, pp. 3459-3468
A Phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077
Authors: Britten, CD Rowinsky, EK Baker, SD Weiss, GR Smith, L Stephenson, J Rothenberg, M Smetzer, L Cramer, J Collins, W Von Hoff, DD Eckhardt, SG
Citation: Cd. Britten et al., A Phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077, CLIN CANC R, 6(1), 2000, pp. 42-49
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies
Authors: Eckhardt, SG Baker, SD Britten, CD Hidalgo, M Siu, L Hammond, LA Villalona-Calero, MA Felton, S Drengler, R Kuhn, JG Clark, GM Smith, SL MacDonald, JR Smith, C Moczygemba, J Weitman, S Von Hoff, DD Rowinsky, EK
Citation: Sg. Eckhardt et al., Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies, J CL ONCOL, 18(24), 2000, pp. 4086-4097
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies
Authors: Britten, CD Rowinsky, EK Baker, SD Agarwala, SS Eckardt, JR Barrington, R Diab, SG Hammond, LA Johnson, T Villalona-Calero, M Fraass, U Statkevich, P Von Hoff, DD Eckhardt, SG
Citation: Cd. Britten et al., A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies, CLIN CANC R, 5(7), 1999, pp. 1629-1637
Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay
Authors: Britten, CD Izbicka, E Hilsenbeck, S Lawrence, R Davidson, K Cerna, C Gomez, L Rowinsky, EK Weitman, S Von Hoff, DD
Citation: Cd. Britten et al., Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay, CANC CHEMOT, 44(2), 1999, pp. 105-110
Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model
Authors: Britten, CD Hilsenbeck, SG Eckhardt, SG Marty, J Mangold, G MacDonald, JR Rowinsky, EK Von Hoff, DD Weitman, S
Citation: Cd. Britten et al., Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model, CANCER RES, 59(5), 1999, pp. 1049-1053
Risultati: 1-8 |